Park Ha Biological Technology (BYAH) Registration Filing summary

Management team and governance

• CEO Xiaoqiu Zhang, CFO Xiaoyan Zhu, and Director Li Wang signed the registration statement, indicating key executive roles and board participation.

• U.S. authorized representative is Colleen A. De Vries, Senior Vice-President at Cogency Global Inc.

• Amended and restated memorandum and articles of association provide for indemnification of directors and officers, except in cases of actual fraud or willful default.

• Board committees include Audit, Compensation, and Nomination Committees, with respective charters filed as exhibits.

Offering details and pricing

• Registration statement filed as Form F-1 (Amendment No. 4) for a proposed public offering in the U.S.

• Offering to commence as soon as practicable after the effective date, with flexibility for post-effective amendments.

• Forward split of ordinary shares at a 1-for-5 ratio, resulting in 25,000,000 shares outstanding and authorization for up to 2,500,000,000 shares.

Underwriters and syndicate

• Form of Underwriting Agreement included as Exhibit 1.1; underwriters to receive certificates for prompt delivery to purchasers at closing.

• Underwriting agreement provides for indemnification of the company and its officers and directors.